Glucagon-Like Peptide-1(GLP-1) Cardiometabolic Expansion Market Global Report 2026

The glucagon-like peptide-1(GLP-1) cardiometabolic expansion market size has grown rapidly in recent years. It will grow from $51.8 billion in 2025 to $59.47 billion in 2026 at a compound annual growth rate (CAGR) of 14.8%. The growth in the historic period can be attributed to rising prevalence of type 2 diabetes, increasing obesity rates globally, development of early glp-1 receptor agonists, growing awareness of metabolic syndrome, expansion of endocrinology treatment guidelines.

The glucagon-like peptide-1(GLP-1) cardiometabolic expansion market size is expected to see rapid growth in the next few years. It will grow to $101.82 billion in 2030 at a compound annual growth rate (CAGR) of 14.4%. The growth in the forecast period can be attributed to expansion of cardiometabolic indications beyond diabetes, increasing adoption of combination incretin therapies, growth in preventive cardiology approaches, rising healthcare focus on obesity-driven comorbidities, integration of precision medicine in metabolic disease treatment. Major trends in the forecast period include expansion of glp-1 therapies into cardiovascular and chronic kidney disease management, increasing adoption of combination incretin therapies for multi-target cardiometabolic control, rising use of glp-1 drugs in obesity-related cardiometabolic risk reduction programs, growth of real-world evidence studies validating long-term cardioprotective benefits of glp-1 agents, increasing integration of glp-1 therapies into digital chronic disease management platforms.

The rising obesity and diabetes prevalence is expected to propel the growth of the glucagon-like peptide-1 (GLP-1) cardiometabolic expansion market going forward. Obesity and diabetes are chronic metabolic disorders that increase body fat levels and impair the body’s ability to regulate blood glucose effectively. The rise in obesity and diabetes is increasing due to reduced physical activity and growing sedentary lifestyles across global populations. The prevalence of obesity and diabetes is increasing the demand for glucagon-like peptide-1 (GLP-1) cardiometabolic therapies, as these drugs help manage blood glucose levels, promote weight reduction, and improve overall cardiometabolic health. For instance, in September 2024, according to the Centers for Disease Control and Prevention (CDC), a US-based national public health agency responsible for disease prevention and health promotion, 23 US states reported adult obesity prevalence rates above 35% in 2023, compared to 22 states in 2022. Therefore, the rising obesity and diabetes prevalence is driving the growth of the glucagon-like peptide-1 (GLP-1) cardiometabolic expansion market.

Major companies operating in the glucagon-like peptide-1 (GLP-1) cardiometabolic expansion market are focusing on developing innovative products such as dual and multi-agonist receptor drugs to enhance weight reduction outcomes, improve metabolic control, and expand therapeutic benefits beyond diabetes into cardiovascular and obesity-related disease management. Dual and multi-agonist receptor drugs refer to therapies that simultaneously activate two or more hormone receptors, including GLP-1, GIP, or glucagon receptors, to improve metabolic functions such as blood glucose regulation, weight loss, and energy balance. For instance, in November 2023, Eli Lilly and Company, a US-based pharmaceutical company, launched Zepbound (tirzepatide) in the United States for chronic weight management in adults with obesity or overweight with weight-related comorbidities. This marked the first approval of a dual GIP and GLP-1 receptor agonist for obesity, significantly expanding the GLP-1 cardiometabolic treatment landscape beyond diabetes into large-scale weight management and metabolic disease intervention.

In December 2024, Novo Holdings A/S, a Denmark-based life sciences investment company, acquired Catalent, Inc. for $16.5 billion. With this acquisition, Novo Holdings aims to strengthen production capabilities for Novo Nordisk A/S’s GLP-1 obesity and diabetes therapies by securing critical fill-finish manufacturing facilities and expanding manufacturing capacity for incretin-based treatments. Catalent, Inc. is a US-based company specializing in fill-finish, formulation, peptide development, and production services for GLP-1 and other cardiometabolic drugs.

Major companies operating in the glucagon-like peptide-1(glp-1) cardiometabolic expansion market are Eli Lilly and Company; Novo Nordisk A/S; AstraZeneca PLC; Boehringer Ingelheim International GmbH; Amgen Inc.; Teva Pharmaceutical Industries Ltd.; Zealand Pharma A/S; Innovent Biologics Inc.; Huadong Medicine Co. Ltd.; Hanmi Pharmaceutical Co. Ltd.; Viking Therapeutics Inc.; Structure Therapeutics Inc.; Sciwind Biosciences Co. Ltd.; Ascletis Pharma Inc.; F. Hoffmann-La Roche AG; Pfizer Inc.; Sanofi S.A.; Regeneron Pharmaceuticals Inc.; Eccogene Inc.; Gan & Lee Pharmaceuticals Co. Ltd.; Altimmune Inc.

North America was the largest region in the glucagon-like peptide-1 (GLP-1) cardiometabolic expansion market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glucagon-like peptide-1(GLP-1) cardiometabolic expansion market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the glucagon-like peptide-1(GLP-1) cardiometabolic expansion market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The glucagon-like peptide-1 (glp-1) cardiometabolic expansion market consists of semaglutide, liraglutide, dulaglutide, tirzepatide, exenatide, and lixisenatide. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The glucagon-like peptide-1(glp-1) cardiometabolic expansion market research report is one of a series of new reports that provides glucagon-like peptide-1(glp-1) cardiometabolic expansion market statistics, including glucagon-like peptide-1(glp-1) cardiometabolic expansion industry global market size, regional shares, competitors with a glucagon-like peptide-1(glp-1) cardiometabolic expansion market share, detailed glucagon-like peptide-1(glp-1) cardiometabolic expansion market segments, market trends and opportunities, and any further data you may need to thrive in the glucagon-like peptide-1(glp-1) cardiometabolic expansion industry. This glucagon-like peptide-1(glp-1) cardiometabolic expansion market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.